{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:10:48Z","timestamp":1794003048332,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30CA236231"],"award-info":[{"award-number":["F30CA236231"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Epidermal growth factor receptor inhibitors (EGFRIs) are used to treat certain cancers but frequently cause cutaneous inflammation that can hinder treatment. This is due in part to the effects of EGFRIs on pro-inflammatory signaling by interferon-\u03b3 (IFN-\u03b3). However, the impact of EGFR ligands (i.e. EGF) on interferon signaling is unclear. The purpose of this study was to investigate the impact of EGF on IFN-\u03b3 transcriptional responses on a genome-wide scale in keratinocytes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>RNA-seq was performed in human keratinocyte (HaCaT) cells treated with IFN-\u03b3, EGF, both, or neither (control). Differentially expressed genes in each treatment group, relative to control, were identified using DESeq2 with a false discovery rate (FDR) threshold of 0.01. Associated biologic processes and gene pathways were examined in gene-set enrichment analyses. Correlations between gene expression were investigated in vivo using RNA-seq data from biopsies of psoriatic and matched normal skin, which were collected from 116 individuals with psoriasis enrolled in the AMAGINE randomized clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 2,792 differentially expressed genes following IFN-\u03b3 treatment, 2,083 (75%) were no longer differentially expressed when EGF was added. IFN-\u03b3-induced genes with significantly lower expression in the presence of EGF included <jats:italic>CXCL10<\/jats:italic>, <jats:italic>IL-6<\/jats:italic>,<jats:italic> IL-1\u00a0A<\/jats:italic>,<jats:italic> HLA-DMA<\/jats:italic>, and <jats:italic>GBP5<\/jats:italic> (activator of the NLRP3 inflammasome); the top enriched biologic processes and pathways were related to MHC-class II antigen presentation (GO:0019886) and cytokine signaling (KEGG:04060). Consistent with our in vitro findings, the expression of <jats:italic>CXCL10<\/jats:italic> and <jats:italic>GBP5<\/jats:italic>, as well as the combined expression z-scores of genes in the enriched MHC-class II and cytokine signaling pathways, were significantly lower in skin biopsies with higher EGF expression compared to those with lower EGF expression among individuals with psoriasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings suggest that the pro-inflammatory IFN-\u03b3-induced transcriptome may be globally attenuated by EGF in keratinocytes, supporting an immunomodulatory role of EGF in the skin. These studies provide insights for the non-canonical immunomodulatory role of EGF signaling and why blocking EGFR signaling (e.g., with EGFRIs) can cause cutaneous inflammation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12864-025-11237-1","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T02:37:01Z","timestamp":1739155021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Epidermal growth factor dampens pro-inflammatory gene expression induced by interferon-gamma in global transcriptome analysis of keratinocytes"],"prefix":"10.1186","volume":"26","author":[{"given":"David C.","family":"Gibbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles R.","family":"McCrary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos S.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Seldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourine A. H.","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"11237_CR1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160\u201374.","journal-title":"N Engl J Med"},{"key":"11237_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/tpj.2011.51","volume":"13","author":"S Parmar","year":"2013","unstructured":"Parmar S, Schumann C, R\u00fcdiger S, Boeck S, Heinemann V, K\u00e4chele V, et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2013;13:181\u20138.","journal-title":"Pharmacogenomics J"},{"key":"11237_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","volume":"56","author":"JC Hu","year":"2007","unstructured":"Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"11237_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803\u201312.","journal-title":"Nat Rev Cancer"},{"key":"11237_CR5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jcp.1041500207","volume":"150","author":"RS Mitra","year":"1992","unstructured":"Mitra RS, Nickoloff BJ. Epidermal growth factor and transforming growth factor-alpha decrease gamma interferon receptors and induction of intercellular adhesion molecule (ICAM-1) on cultured keratinocytes. J Cell Physiol. 1992;150:264\u20138.","journal-title":"J Cell Physiol"},{"key":"11237_CR6","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-10-3283","volume":"17","author":"BP Pollack","year":"2011","unstructured":"Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res. 2011;17:4400\u201313.","journal-title":"Clin Cancer Res"},{"key":"11237_CR7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.febslet.2007.03.002","volume":"581","author":"E Burova","year":"2007","unstructured":"Burova E, Vassilenko K, Dorosh V, Gonchar I, Nikolsky N. Interferon gamma-dependent transactivation of epidermal growth factor receptor. FEBS Lett. 2007;581:1475\u201380.","journal-title":"FEBS Lett"},{"key":"11237_CR8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett SW, Andrews S. FastQ screen: a tool for multi-genome mapping and quality control. F1000Res. 2018;7:1338.","journal-title":"F1000Res"},{"key":"11237_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"11237_CR10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"11237_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"11237_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279\u201384.","journal-title":"Behav Brain Res"},{"key":"11237_CR13","doi-asserted-by":"crossref","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199\u2013205.","journal-title":"Nucleic Acids Res"},{"key":"11237_CR14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","volume":"145","author":"LE Tomalin","year":"2020","unstructured":"Tomalin LE, Russell CB, Garcet S, Ewald DA, Klekotka P, Nirula A, et al. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. J Allergy Clin Immunol. 2020;145:922\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"11237_CR15","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the Gene expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23:1846\u20137.","journal-title":"Bioinformatics"},{"key":"11237_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4161\/onci.1.1.18073","volume":"1","author":"BP Pollack","year":"2012","unstructured":"Pollack BP. EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response. Modifiers? Oncoimmunology. 2012;1:71\u20134.","journal-title":"Modifiers? Oncoimmunology"},{"key":"11237_CR17","doi-asserted-by":"crossref","first-page":"ra19910","DOI":"10.1126\/scitranslmed.3005773","volume":"5","author":"F Mascia","year":"2013","unstructured":"Mascia F, Lam G, Keith C, Garber C, Steinberg SM, Kohn E, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med. 2013;5:ra19910\u201310.","journal-title":"Sci Transl Med"},{"key":"11237_CR18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","volume":"128","author":"S Pastore","year":"2008","unstructured":"Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol. 2008;128:1365\u201374.","journal-title":"J Invest Dermatol"},{"key":"11237_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","volume":"163","author":"F Mascia","year":"2003","unstructured":"Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003;163:303\u201312.","journal-title":"Am J Pathol"},{"key":"11237_CR20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00204-014-1244-4","volume":"88","author":"S Pastore","year":"2014","unstructured":"Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol. 2014;88:1189\u2013203.","journal-title":"Arch Toxicol"},{"key":"11237_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CCC.2008.n.005","volume":"7","author":"D Bianchini","year":"2008","unstructured":"Bianchini D, Jayanth A, Chua YJ, Cunningham D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer. 2008;7:33\u201343.","journal-title":"Clin Colorectal Cancer"},{"key":"11237_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000342203","volume":"225","author":"JU Shin","year":"2012","unstructured":"Shin JU, Park JH, Cho BC, Lee JH. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Dermatology. 2012;225:135\u201340.","journal-title":"Dermatology"},{"key":"11237_CR23","first-page":"219","volume":"182","author":"JH Lee","year":"2020","unstructured":"Lee JH, Ju HJ, Kwon HS, Jung HM, Kim GM, Bae JM, et al. Efficacy of topical epidermal growth factor cream for patients with epidermal growth factor receptor inhibitor-induced acneiform eruption: a randomized controlled trial. Br J Dermatol. 2020;182:219\u201321.","journal-title":"Br J Dermatol"},{"key":"11237_CR24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/ijd.12488","volume":"53","author":"HK Kim","year":"2014","unstructured":"Kim HK, Yeo IK, Li K, Kim BJ, Kim MN, Hong CK. Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial. Int J Dermatol. 2014;53:1031\u20136.","journal-title":"Int J Dermatol"},{"key":"11237_CR25","doi-asserted-by":"crossref","first-page":"11895","DOI":"10.1038\/s41598-018-30404-x","volume":"8","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Choi MJ, Bak DH, Lee BC, Ko EJ, Ahn GR, et al. Topical administration of EGF suppresses immune response and protects skin barrier in DNCB-induced atopic dermatitis in NC\/Nga mice. Sci Rep. 2018;8:11895.","journal-title":"Sci Rep"},{"key":"11237_CR26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1742-481X.2009.00622.x","volume":"6","author":"J Berlanga-Acosta","year":"2009","unstructured":"Berlanga-Acosta J, Gavilondo-Cowley J, L\u00f3pez-Saura P, Gonz\u00e1lez-L\u00f3pez T, Castro-Santana MD, L\u00f3pez-Mola E, et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6:331\u201346.","journal-title":"Int Wound J"},{"key":"11237_CR27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","volume":"194","author":"J Flier","year":"2001","unstructured":"Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194:398\u2013405.","journal-title":"J Pathol"},{"key":"11237_CR28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41419-018-0621-y","volume":"9","author":"W Zhang","year":"2018","unstructured":"Zhang W, Yi X, An Y, Guo S, Li S, Song P, et al. MicroRNA-17-92 cluster promotes the proliferation and the chemokine production of keratinocytes: implication for the pathogenesis of psoriasis. Cell Death Dis. 2018;9:567.","journal-title":"Cell Death Dis"},{"key":"11237_CR29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000357780","volume":"21","author":"R Vazirinejad","year":"2014","unstructured":"Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation. 2014;21:322\u201330.","journal-title":"Neuroimmunomodulation"},{"key":"11237_CR30","doi-asserted-by":"publisher","unstructured":"Kim JM, Ji JH, Kim YS, Lee S, Oh SY, Huh SJ, et al. rhEGF Treatment\u00a0Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects. Cancers (Basel). 2020;12(11):3120. https:\/\/doi.org\/10.3390\/cancers12113120.","DOI":"10.3390\/cancers12113120"}],"updated-by":[{"DOI":"10.1186\/s12864-025-11457-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000}}],"container-title":["BMC Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-11237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12864-025-11237-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-11237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T14:03:20Z","timestamp":1742825000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenomics.biomedcentral.com\/articles\/10.1186\/s12864-025-11237-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11237"],"URL":"https:\/\/doi.org\/10.1186\/s12864-025-11237-1","relation":{},"ISSN":["1471-2164"],"issn-type":[{"value":"1471-2164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12864-025-11457-5","URL":"https:\/\/doi.org\/10.1186\/s12864-025-11457-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board (IRB) approval was not required as this was non-human subjects research.\u00a0The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}